Chemistry Radiochemistry

Professor Ogawa, Mr. Echigo (PhD student), and their colleagues in Kanazawa University report in Eur J Nucl Med Mol Imaging that combination of an At-211-labeled agent with immune checkpoint blockade significantly enhances its therapeutic effect. This strategy represents a promising advancement in the development of next-generation cancer therapies that combine targeted alpha therapy and immunotherapy.